Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 8/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | MDH2 | P40926 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23391438 | 1.00 | MARS2 (0.49) | MARS2ROCK2ROCK1FPR2IDH1 | |
| SCHEMBL20595909 | 0.89 | MARS2 (0.52) | MARS2FPR2 | |
| SCHEMBL30145285 | 0.89 | MARS2 (0.52) | MARS2FPR2 | |
| SCHEMBL20595883 | 0.86 | DPP4 (0.39) | MARS2ROCK2ROCK1IDH1CHEK1 | |
| SCHEMBL20596070 | 0.84 | AMY1A (0.43) | DPP4DPP8DPP9 | |
| SCHEMBL23391441 | 0.83 | MARS2 (0.46) | MARS2 | |
| SCHEMBL30145077 | 0.83 | MARS2 (0.46) | MARS2 | |
| SCHEMBL20595887 | 0.82 | TNKS (0.36) | MARS2ROCK2ROCK1IDH1TNIK | |
| SCHEMBL23391415 | 0.81 | DPP4 (0.36) | IDH1CHRM5TNIKDPP4DPP8 | |
| SCHEMBL20595700 | 0.81 | DPP4 (0.37) | MARS2IDH1CHRM5TNIKDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885ROCK2 3865/4885ROCK1 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.